Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

Hematopathology Tumor Board: Case Studies and Diagnostic Challenges …

UChicago Medicine

G. Venkataraman, A. Perry, K. Cahill, A. Akmatbekov, L. Wu

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Allo-HSCT Conditioning Regimens: Current Status and Future Directions

Rush University Medical Center

C. Brunstein

Pre-Transplant Management of High-Risk AML

Vanderbilt University Medical Center (VUMC)

K. Fedorov

Selection and Sequencing of Chronic GVHD Therapy

Rush University Medical Center

S. Kosuri

Steroid-Refractory GvHD Management: When to Switch From Steroids

Giuseppe Francesco Milone

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon

Correlation of PROs and Organ Response in Belumosudil-Treated cGVHD:…

Levanto Schachter

Understanding New Strategies to Prevent and Manage Chronic GVHD

2024 ASCO® Annual Meeting Insights Hub

B. Hamilton

Managing Relapse After CAR-T Therapy in Lymphoma: Strategies and Con…

Vanderbilt University Medical Center (VUMC)

B. Dholaria

Age Limits in Stem Cell Transplants and Cell Therapy

Vanderbilt University Medical Center (VUMC)

R. Jayani

Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patie…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

Unmet Needs in GvHD and the Role of Axatilimab

Jose Perez Simon

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay